---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-088203"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:18:44.953866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sana Q4 net loss $58.8M; UP421 islet cells function at 1 year no immunosuppression; new $150M ATM filed

## Summary
- UP421 hypoimmune islet cells in type 1 diabetes show C-peptide production, immune evasion at 1 year without immunosuppression.
- Expect to file IND for SC451 (stem cell-derived islet therapy) and begin Phase 1 trial this year.
- SG293 in vivo CAR T: NHP data show deep B-cell depletion; first-in-human data expected this year.
- Q4 2025 net loss $58.8M ($0.21/shr); R&D $34.9M; cash $138.4M; runway into late 2026.
- Entered new ATM agreement with TD Cowen for up to $150M; raised $133.7M gross from equity in 2025.

## SEC filing metadata
- accession: 0001193125-26-088203
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/0001193125-26-088203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/sana-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-088203
- JSON: https://secwatch.observer/filing/0001193125-26-088203.json
- Plain text: https://secwatch.observer/filing/0001193125-26-088203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.